Peakdale Completes Peakexplorer™ GPCR Collection for Drug Discovery
News Jan 31, 2006
Peakdale Molecular Ltd has announced the completion of its peakexplorer™ G-Protein Coupled Receptor library of screening compounds.
G6, its sixth and final release, now brings the total collection to 6,500 fully characterised and purified, drugs-like compounds.
Based around 34 major chemotypes, the peakexplorer library has been designed to address gaps in commercially available compound collections and to provide diversity in drug discovery.
These synthetic capabilities have been strengthened through the collaboration with De Novo Pharmaceuticals, bringing in silico pharmacophore modelling and virtual screening algorithms to enhance the library design and characterisation processes.
Commenting on the library’s success, Kim Morrison, CEO, noted, "This collaboration has been extremely successful and has provided us with a great learning curve on running these types of partnerships."
"We are using this experience to further refine our approach to designing focused arrays against specific targets to speed up drug discovery."
Having completed the peakexplorer GPCR range Peakdale is now turning its attention to synthesising a kinase library and also designing peakfinder™ chemogenetic arrays.
These will be collections of drug-like molecules, selectively designed to enhance receptor-ligand interactions.
The combination of Peakdale’s synthetic and medicinal chemistry expertise, with the addition of in-house computational design tools, will mean these arrays will be based around novel molecules and incorporate ADMET filters.
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019